 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || RG6232 / Roche
P1 data, Journal, Metastases: Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. (Pubmed Central) - Apr 5, 2024
P1
This study provides important insights into how the use of active drug PK assays, coupled with mechanistic follow-up, can inform and enable ongoing benefit/risk assessment for individuals participating in FIH dose-escalation trials. Translational studies that lead to a better understanding of the underlying biology of cognate T- and B-cell interactions, ultimately resulting in ADA development to novel biotherapeutics, are needed.
- || RG6232 / Roche
Trial completion, Trial completion date, Trial primary completion date, Metastases: A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov) - Oct 3, 2022
P1, N=20, Completed, Sponsor: Hoffmann-La Roche
Translational studies that lead to a better understanding of the underlying biology of cognate T- and B-cell interactions, ultimately resulting in ADA development to novel biotherapeutics, are needed. Active, not recruiting --> Completed | Trial completion date: Jan 2023 --> Jul 2022 | Trial primary completion date: Jan 2023 --> Jul 2022
- || RG6232 / Roche
Enrollment change, Metastases: A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov) - Mar 18, 2022
P1, N=20, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial completion date: Jan 2023 --> Jul 2022 | Trial primary completion date: Jan 2023 --> Jul 2022 N=310 --> 20
- || RG6232 / Roche
Enrollment closed, Metastases: A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov) - Mar 7, 2022
P1, N=310, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=310 --> 20 Recruiting --> Active, not recruiting
- || RG6232 / Roche
Trial completion date, Trial primary completion date, Metastases: A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov) - Dec 2, 2021
P1, N=310, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial completion date: Sep 2023 --> Jan 2023 | Trial primary completion date: Sep 2023 --> Jan 2023
- ||| RG6232 / Roche
Enrollment open, Metastases: A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov) - Oct 19, 2020
P1, N=310, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Sep 2023 --> Jan 2023 | Trial primary completion date: Sep 2023 --> Jan 2023 Not yet recruiting --> Recruiting
- ||| RG6232 / Roche
New P1 trial, Metastases: A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (clinicaltrials.gov) - Sep 15, 2020
P1, N=310, Not yet recruiting, Sponsor: Hoffmann-La Roche